Shin Poong Pharm.Co.,Ltd.

KRX:019170.KS

10600 (KRW) • At close November 13, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) KRW.

20232022202120202019201820172016201520142013201220112010200920082007
Revenue 200,228.583209,287.628189,237.235197,750.767189,721.696187,389.168184,998.4194,147.338195,950.486220,291.938215,962.84221,169.38229,693.072232,060.469217,255.761188,135.653165,922.224
Cost of Revenue 121,608.743131,314.541111,849.721121,223.562113,536.906111,504.09104,877.354106,220.013109,265.364119,328.328120,449.943131,781.322126,557.925121,330.706112,105.52492,307.6986,023.353
Gross Profit 78,619.83977,973.08777,387.51476,527.20576,184.7975,885.07880,121.04787,927.32586,685.122100,963.6195,512.89789,388.058103,135.148110,729.763105,150.23795,827.96379,898.871
Gross Profit Ratio 0.3930.3730.4090.3870.4020.4050.4330.4530.4420.4580.4420.4040.4490.4770.4840.5090.482
Reseach & Development Expenses 56,019.40430,382.74517,334.4385,622.3015,966.5034,869.8224,625.7186,386.4569,136.6375,751.3153,585.0366,272.6384,823.1065,093.91145.019656.595867.64
General & Administrative Expenses 7,589.366111,991.7735,955.0335,492.7565,295.9045,185.4065,314.1216,238.7696,432.424,570.1885,833.8486,791.7816,663.46111,580.47711,044.42914,482.66612,059.171
Selling & Marketing Expenses 29,276.52428,362.98523,996.08721,912.38220,795.3118,946.02421,620.62122,313.41320,359.66920,354.15818,063.26916,765.06617,023.47614,973.99824,020.79721,617.89818,589.503
SG&A 71,576.084111,991.77329,951.1227,405.13826,091.21424,131.4326,934.74228,552.18226,792.08924,924.34623,897.11723,556.84723,686.93726,554.47535,065.22636,100.56430,648.674
Other Expenses 0-30,382.74544,408.3635,654.2538,524.92739,131.206186.71-10,494.791204.305-29.764459.089-293.761127.032-886.11-569.623-583.763-116.064
Operating Expenses 127,595.488111,991.77391,693.91868,681.68970,582.64468,132.45872,306.32178,358.85782,449.51381,711.85970,701.51165,153.70864,834.66266,755.70669,883.49264,591.73260,720.973
Operating Income -47,392.405-34,018.686-9,044.91611,348.2738,424.49810,685.5027,814.7259,568.4684,235.60919,251.75124,811.38624,234.3538,295.42243,974.05735,266.74431,236.23319,177.9
Operating Income Ratio -0.237-0.163-0.0480.0570.0440.0570.0420.0490.0220.0870.1150.110.1670.1890.1620.1660.116
Total Other Income Expenses Net -6,049.393-762.851-720.039-3,008.484-1,305.886-4,065.787-6,113.802-14,619.42-2,352.801-5,745.035-5,136.595-6,180.67-6,802.519-5,630.59-4,460.049-10,803.371-3,718.961
Income Before Tax -53,441.798-34,781.537-8,985.6458,339.797,118.6125,182.3191,700.923-3,703.1672,165.47713,506.71619,674.79118,053.68131,492.90338,343.46730,806.69520,432.86215,458.939
Income Before Tax Ratio -0.267-0.166-0.0470.0420.0380.0280.009-0.0190.0110.0610.0910.0820.1370.1650.1420.1090.093
Income Tax Expense 3,830.735527.2922,540.3663,294.0531,723.6252,368.664780.74414,895.066688.79910,152.52214,189.3393,715.156,629.69816,587.4419,717.28,343.6616,624.937
Net Income -57,325.388-35,308.829-11,526.0115,002.8055,323.8272,803.78904.889-18,591.6991,476.2163,349.6175,437.65114,377.4924,866.2421,734.26321,052.45412,051.0018,843.13
Net Income Ratio -0.286-0.169-0.0610.0250.0280.0150.005-0.0960.0080.0150.0250.0650.1080.0940.0970.0640.053
EPS -1,119-688.79-224.8499.4106.535625-392.023599133.65353.18611.62530.57498.93285.23209.13
EPS Diluted -1,118.28-688.79-224.8499.4106.535625-392.023599133.65353.18611.62530.57498.93285.23209.13
EBITDA -37,067.259-22,223.3231,274.74721,041.49722,869.15119,118.21517,990.4310,324.04719,486.22232,314.44136,392.83132,052.18546,010.16952,285.21144,068.80432,332.17725,704.872
EBITDA Ratio -0.1850.3730.0190.1190.1090.1180.0980.0470.0950.1540.180.1530.2070.2250.2020.1850.155